In the past funding period, the City of Hope Comprehensive Cancer Center distributed awards for 12 pilot projects in the amount of $485,000 to encourage collaborative projects or high-risk research of Center members. Grants exceeding $2,800,000 resulted from several of these collaborations, including one project grant of our new lymphoma SPORE and several R01s. The Center also provided $100,000 over 2 years in support of the developing core, Clinical Immunobiology Correlative Studies Laboratory, which is a new shared resource in this renewal application. During the next funding period, the COHCCC has undertaken an ambitious goal: to accelerate its translational research activities through recruitment and program and infrastructure development so that we increase--with speed, safety, and effectiveness -- the density of innovative laboratory discoveries reaching in-house clinical trials. We propose to use our developmental funds, a requested total of $250,000 yearly, to support programmatic growth as follows: * $100,000 yearly for 2 to 3 projects focused in the three clinical programs?breast, prostate, and thoracic malignancies?that we have targeted for evolution into Center research programs on the occasion of the next CCSG renewal. * Each project to pair a clinical and laboratory researcher in the disease area We will advance our infrastructure by developing three new shared resources: * High Throughput Screening to identify small molecular modulators of cancer therapeutics targets identified by Center investigators ($50,000/year for 3 years) * Synthetic and Biopolymer Chemistry to pursue small-molecule structure/activity relationships ($50,000/year for 3 years) * Survey Research to assist our population sciences investigators in gathering data from dispersed research subjects in an efficient process that is compliant with institutional and governmental regulations ($50,000/year for 3 years)

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA033572-29
Application #
8374891
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2013-04-24
Budget Start
2011-12-01
Budget End
2012-11-30
Support Year
29
Fiscal Year
2012
Total Cost
$210,437
Indirect Cost
$44,622
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Gu, Ying; Zhang, Jiawei; Ma, Xiaoxiao et al. (2017) Stabilization of the c-Myc Protein by CAMKII? Promotes T Cell Lymphoma. Cancer Cell 32:115-128.e7
Cao, Pengpeng; Mooney, Rachael; Tirughana, Revathiswari et al. (2017) Intraperitoneal Administration of Neural Stem Cell-Nanoparticle Conjugates Targets Chemotherapy to Ovarian Tumors. Bioconjug Chem 28:1767-1776
Mohanty, Suchismita; Mohanty, Atish; Sandoval, Natalie et al. (2017) Cyclin D1 depletion induces DNA damage in mantle cell lymphoma lines. Leuk Lymphoma 58:676-688
Wittenberg, Elaine; Ferrell, Betty; Koczywas, Marianna et al. (2017) Pilot Study of a Communication Coaching Telephone Intervention for Lung Cancer Caregivers. Cancer Nurs :
Yuan, Yuan; Vora, Nilesh; Sun, Can-Lan et al. (2017) Association of Pre-Chemotherapy Peripheral Blood Pro-Inflammatory and Coagulation Factors with Physical Function in Women with Breast Cancer. Oncologist 22:1189-1196
Deng, Ruishu; Hurtz, Christian; Song, Qingxiao et al. (2017) Extrafollicular CD4+ T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease. Nat Commun 8:978
He, Zhiheng; Ma, Jian; Wang, Ruiqing et al. (2017) A two-amino-acid substitution in the transcription factor ROR?t disrupts its function in TH17 differentiation but not in thymocyte development. Nat Immunol 18:1128-1138
Kortylewski, Marcin; Moreira, Dayson (2017) Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities. Cancer Immunol Immunother 66:979-988
Somlo, George; Frankel, Paul H; Arun, Banu K et al. (2017) Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. Clin Cancer Res 23:4066-4076
Slavin, Thomas P; Neuhausen, Susan L; Nehoray, Bita et al. (2017) The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes. Fam Cancer :

Showing the most recent 10 out of 1277 publications